1 - 5 pack(s) - $599.00 USD
6 - 10 pack(s) - $589.00 USD
11 - 20 pack(s) - $584.00 USD
21+ pack(s) - $579 USD
units to my shopping cart.
Save $60.00 if you add 5 additional units.
Generic name: sodium hyaluronate
Brand name: Hymovis
Drug class: Viscosupplementation agent
Dosage form: 3ml/5ml prefilled syringe
Manufacturer: Fidia Pharma USA Inc.
FDA Approval: August 28, 2015
Hymovis is high-molecular weight viscoelastic hyaluronan-based solution that is indicated for the treatment of pain in patients with knee osteoarthritis that have failed to respond to simple pain relievers and other conventional, non-invasive treatments. The solution should be administered into the knee joint via an intra-articular injection by a trained clinical professional. Hyaluronan is a natural polysaccharide that is found in very high amounts in the skin, eyes, joints, and other connective tissues. It is contained in the synovial fluid in the joints, where the fluid acts as a lubricant and shock absorber. The quality of hyaluronan in patients with osteoarthritis may be different from normal. This restricts the joints from functioning properly and causes pain. Hymovis, through its hyaluronan content, improves the functioning of this fluid and helps provide pain relief.
Hymovis is only indicated for providing pain relief in patients with knee osteoarthritis. Its safety and efficacy in other joints have not been established. This drug should not be injected in areas with an active infection, inflammation, or other skin diseases. Post-injection reactions may occur; these reactions can include transient pain and swelling. Some patients with inflammatory joint conditions may experience increase in inflammation following an injection of hyaluronan. Patients should refrain from engaging in strenuous or prolonged physical activity within 48 hours following treatment. Each pack of Hymovis contains two 5ml syringes that each have a 3ml dose of Hymovis. The second syringe (and its content) must be injected a week after the contents of the first syringe have been administered.